Eastwood Bio-Medical Canada Inc (EBM) - Net Assets

Latest as of April 2025: CA$-1.49 Million CAD

Based on the latest financial reports, Eastwood Bio-Medical Canada Inc (EBM) has net assets worth CA$-1.49 Million CAD as of April 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$235.60K) and total liabilities (CA$1.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CA$-1.49 Million
% of Total Assets -634.44%
Annual Growth Rate N/A
5-Year Change -382.33%
10-Year Change -134.8%
Growth Volatility 40.71

Eastwood Bio-Medical Canada Inc - Net Assets Trend (2013–2024)

This chart illustrates how Eastwood Bio-Medical Canada Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Eastwood Bio-Medical Canada Inc (2013–2024)

The table below shows the annual net assets of Eastwood Bio-Medical Canada Inc from 2013 to 2024.

Year Net Assets Change
2024-10-31 CA$-1.30 Million -54.22%
2023-10-31 CA$-840.80K -185.79%
2022-10-31 CA$-294.20K -103.85%
2021-10-31 CA$-144.32K -131.42%
2020-10-31 CA$459.27K -64.99%
2019-10-31 CA$1.31 Million -30.56%
2018-10-31 CA$1.89 Million -31.61%
2017-10-31 CA$2.76 Million -13.88%
2016-10-31 CA$3.21 Million -13.92%
2015-10-31 CA$3.73 Million -6.53%
2014-10-31 CA$3.99 Million +2013.97%
2013-10-31 CA$-208.29K --

Equity Component Analysis

This analysis shows how different components contribute to Eastwood Bio-Medical Canada Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 578526000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (October 2024)

Component Amount Percentage
Other Components CA$4.70 Million %
Total Equity CA$-1.30 Million 100.00%

Eastwood Bio-Medical Canada Inc Competitors by Market Cap

The table below lists competitors of Eastwood Bio-Medical Canada Inc ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Eastwood Bio-Medical Canada Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from -840,796 to -1,296,666, a change of -455,870.
  • Net loss of 455,870 reduced equity.
  • Other comprehensive income decreased equity by 9,514.
  • Other factors increased equity by 9,514.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CA$-455.87K -35.16%
Other Comprehensive Income CA$-9.51K -0.73%
Other Changes CA$9.51K +0.73%
Total Change CA$- %

Book Value vs Market Value Analysis

This analysis compares Eastwood Bio-Medical Canada Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2013-10-31 CA$0.00 CA$0.70 x
2014-10-31 CA$0.08 CA$0.70 x
2015-10-31 CA$0.06 CA$0.70 x
2016-10-31 CA$0.05 CA$0.70 x
2017-10-31 CA$0.04 CA$0.70 x
2018-10-31 CA$0.03 CA$0.70 x
2019-10-31 CA$0.02 CA$0.70 x
2020-10-31 CA$0.01 CA$0.70 x
2021-10-31 CA$0.00 CA$0.70 x
2022-10-31 CA$0.00 CA$0.70 x
2023-10-31 CA$-0.01 CA$0.70 x
2024-10-31 CA$-0.02 CA$0.70 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Eastwood Bio-Medical Canada Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -64.93%
  • • Asset Turnover: 2.56x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-27.45%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2013 0.00% -24.00% 0.16x 0.00x CA$-118.45K
2014 -13.02% -112.48% 0.11x 1.02x CA$-917.77K
2015 -6.99% -21.95% 0.31x 1.03x CA$-633.01K
2016 -14.61% -100.98% 0.14x 1.01x CA$-789.23K
2017 -17.73% -102.06% 0.17x 1.02x CA$-765.84K
2018 -45.63% -115.86% 0.33x 1.19x CA$-1.05 Million
2019 -44.19% -44.84% 0.78x 1.26x CA$-710.85K
2020 -187.26% -119.73% 0.77x 2.03x CA$-905.96K
2021 0.00% -62.31% 1.42x 0.00x CA$-596.90K
2022 0.00% -12.35% 2.22x 0.00x CA$-131.16K
2023 0.00% -62.98% 1.77x 0.00x CA$-462.52K
2024 0.00% -64.93% 2.56x 0.00x CA$-326.20K

Industry Comparison

This section compares Eastwood Bio-Medical Canada Inc's net assets metrics with peer companies in the Food Distribution industry.

Industry Context

  • Industry: Food Distribution
  • Average net assets among peers: $95,432,294
  • Average return on equity (ROE) among peers: -34.16%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Eastwood Bio-Medical Canada Inc (EBM) CA$-1.49 Million 0.00% N/A $34.88 Million
Century Global Commodities Corp (CNT) $144.45 Million -4.29% 0.03x $3.42 Million
Ceres Global Ag Corp (CRP) $150.95 Million 6.20% 0.72x $137.69 Million
Colabor Group Inc. (GCL) $85.76 Million 3.83% 0.54x $2.95 Million
Organto Foods Incorporated (OGO) $562.47K -142.39% 4.11x $97.68 Million

About Eastwood Bio-Medical Canada Inc

V:EBM Canada Food Distribution
Market Cap
$34.88 Million
CA$48.22 Million CAD
Market Cap Rank
#25824 Global
#781 in Canada
Share Price
CA$0.70
Change (1 day)
-17.65%
52-Week Range
CA$0.30 - CA$1.10
All Time High
CA$8.48
About

Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. The company distributes Eleotin, which provides natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. Its licensed products include Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, a… Read more